Group 1 - The core point of the announcement is that Qianjiang Yong'an Pharmaceutical Co., Ltd. has signed an absorption merger agreement with its wholly-owned subsidiary Hubei Ling'an Technology Co., Ltd. to optimize management structure and improve operational efficiency [2][3] - The merger will result in the cancellation of Ling'an Technology's legal entity, with all assets, debts, and rights being inherited by Yong'an Pharmaceutical [2][4] - The merger will not affect the company's name, registered capital, shareholding structure, or changes in the board of directors and senior management [2][3] Group 2 - The merger is set to take effect on the completion date, which will be determined after fulfilling internal decision-making procedures, signing the merger agreement, and obtaining necessary government approvals [3][4] - The registered capital of Yong'an Pharmaceutical before the merger is RMB 294,682,500, while Ling'an Technology's registered capital is RMB 16,670,000. Post-merger, Yong'an's registered capital remains unchanged [7] - The merger process includes notifying creditors, publishing merger announcements, and completing necessary legal and administrative procedures [8][9] Group 3 - Creditors have the right to claim debts or request guarantees within thirty days of receiving notification or within forty-five days from the announcement if no notification is received [12] - Specific documentation is required for creditors to assert their claims, including identification and authorization documents [13][14] - The merger agreement and related documents will be available for review [15]

证券代码：002365 证券简称：永安药业 公告编号：2026-07 潜江永安药业股份有限公司 关于与全资子公司湖北凌安科技有限公司签订 《吸收合并协议》及通知债权人的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、吸收合并相关情况 为优化管理架构，提高运营效率，降低管理成本，整合优质资源，潜江永安 药业股份有限公司（以下简称"公司"或"永安药业"）分别于 2026 年 1 月 6 日召开了第七届董事会第十二次临时会议、2026 年 1 月 22 日召开了 2026 年第 一次临时股东会，审议通过了《关于吸收合并全资子公司湖北凌安科技有限公司 的议案》，永安药业将对下属全资子公司湖北凌安科技有限公司（以下简称"凌 安科技"）实施整体吸收合并。本次吸收合并完成后，凌安科技法人主体资格将 依法予以注销，其全部资产、债权、债务、业务、人员及其他一切权利与义务等 由公司依法承继。本次吸收合并不涉及公司名称、注册资本、股权结构及董事会、 高级管理人员变化。 具体内容见公司在《证券时报》、《中国证券报》、《上海证券报》及巨潮 资讯网（http://www.cni ...

证券日报网讯1月23日，永安药业（002365）在互动平台回答投资者提问时表示，截至2026年1月20日， 公司股东人数为49873户。 ...

Group 1 - The company held its first extraordinary general meeting of shareholders on January 22, 2026, with no proposals being rejected [2] - A total of 472 shareholders attended the meeting, representing 77,785,386 shares, which is 26.9018% of the total voting shares [3][6] - The meeting was conducted in compliance with relevant laws and regulations, ensuring the legitimacy of the proceedings [13] Group 2 - The proposal to absorb the wholly-owned subsidiary Hubei Ling'an Technology Co., Ltd. was approved, with 77,522,786 shares in favor, accounting for 99.6624% of the valid votes [8][10] - The proposal to amend the "Compensation Management System for Directors and Senior Management" was also approved, with 77,422,086 shares in favor, representing 99.5329% of the valid votes [11][12] Group 3 - The meeting included participation from the company's directors, senior management, and witnessing lawyers, ensuring a comprehensive representation [7] - The legal opinion provided by Shanghai Jintiancheng (Wuhan) Law Firm confirmed that the meeting's procedures and voting results were valid and in accordance with the law [13][14]

上海市锦天城（武汉）律师事务所 关于潜江永安药业股份有限公司 二○二六年第一次临时股东会的 法律意见书 上海市锦天城（武汉）律师事务所（以下简称"本所"）接受潜江永安药业 股份有限公司（以下简称"公司"）的委托，委派本律师出席公司二○二六年第 一次临时股东会（下简称"本次股东会"），就公司召开本次股东会的有关事宜， 根据《中华人民共和国公司法》（以下简称《公司法》）《上市公司股东会规则》 等法律、法规、规章和其他规范性文件以及《潜江永安药业股份有限公司章程》 （以下简称《公司章程》）的有关规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东会所涉及的相关事项 进行了必要的核查和验证，核查了本所认为出具该法律意见书所需的相关文件、 资料，并参加了公司本次股东会的全过程。本所保证本法律意见书所认定的事实 真实、准确、完整，所发表的结论性意见合法、准确，不存在虚假记载、误导性 陈述或者重大遗漏，并愿意承担相应法律责任。 本所同意将本法律意见书与本次股东 ...

证券代码：002365 证券简称：永安药业 公告编号：2026-06 潜江永安药业股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决提案的情形； 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、召开时间： 现场会议召开时间：2026年1月22日14:30:00 网络投票时间：2026年1月22日 （1）通过深圳证券交易所交易系统进行网络投票的具体时间为：2026年1 月22日上午9:15—9:25,9:30-11:30 和下午13:00—15:00。 （2）通过深圳证券交易所互联网投票系统投票的时间为：2026年1月22日 9:15—15:00期间的任意时间。 2、现场会议召开地点：湖北省潜江经济开发区广泽大道2号潜江永安药业股 份有限公司（以下简称"公司"）二楼会议室 3、召开方式：本次股东会采取现场投票和网络投票相结合的方式。 4、股权登记日：2026年1月16日（星期五） 5、召集人：公司董事会； 6、主持人：公司董事长 ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.77% on January 20, with Kangzhi Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Hanshang Group (Code: 600774) with a closing price of 11.64, up 10.02% and a trading volume of 438,600 shares, totaling 489 million yuan [1] - Tainkang (Code: 301263) with a closing price of 32.71, up 7.04% and a trading volume of 138,300 shares, totaling 437 million yuan [1] - Sitaili (Code: 603520) with a closing price of 10.58, up 2.52% and a trading volume of 210,900 shares, totaling 225 million yuan [1] - Conversely, significant decliners included: - Kangyi Pharmaceutical (Code: 300086) with a closing price of 10.44, down 5.86% and a trading volume of 447,100 shares [2] - Dizhe Pharmaceutical (Code: 688192) with a closing price of 62.72, down 5.10% and a trading volume of 42,700 shares [2] - Guangji Pharmaceutical (Code: 000952) with a closing price of 7.52, down 4.93% and a trading volume of 292,200 shares [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 1.348 billion yuan from institutional investors, while retail investors contributed a net inflow of 1.109 billion yuan [2] - The capital flow for specific stocks indicated: - Huabang Health (Code: 002004) had a net inflow of 88.38 million yuan from institutional investors, but a net outflow of 73.07 million yuan from retail investors [3] - Fuxiang Pharmaceutical (Code: 300497) recorded a net inflow of 57.88 million yuan from institutional investors, with a net outflow of 102 million yuan from retail investors [3] - Xinqiao Pharmaceutical (Code: 000756) had a net inflow of 25.08 million yuan from institutional investors, but also saw a net outflow of 15.54 million yuan from retail investors [3]

Group 1 - The core point of the article is that Yong'an Pharmaceutical (002365) has disclosed its shareholder count, which is projected to reach 49,527 households by December 31, 2025 [1]

Group 1 - The company approved the absorption merger of its wholly-owned subsidiary, Hubei Ling'an Technology Co., Ltd., which will be dissolved after the merger, with all assets, debts, and rights transferred to the company [1][28]. - The board meeting held on January 6, 2026, had all seven directors participating and unanimously approved the merger proposal [1][28]. - The merger aims to optimize management structure, improve operational efficiency, and reduce management costs [28][33]. Group 2 - The company approved a daily related transaction with Hubei Tian'an Daily Chemical Co., Ltd., with a total transaction amount not exceeding RMB 40 million for the year 2026 [3][16]. - The board meeting saw two related directors abstaining from voting, with five votes in favor and none against [3][16]. - The independent directors had previously reviewed and approved the related transaction proposal before it was presented to the board [4][24]. Group 3 - The company also approved a framework agreement with Hubei Yongbang Engineering Technology Co., Ltd. for equipment processing and manufacturing, with a total amount not exceeding RMB 20 million for 2026 [4][37]. - Similar to the previous transaction, two related directors abstained from voting, and the proposal was approved with five votes in favor [4][37]. - The independent directors confirmed that the transaction is necessary for the company's production needs and does not harm the interests of shareholders [56]. Group 4 - The company scheduled its first extraordinary shareholders' meeting for January 22, 2026, to discuss the approved proposals [14][60]. - The meeting will allow shareholders to vote both in person and via online platforms, ensuring compliance with relevant regulations [60][70]. - The company will provide a detailed voting process for shareholders participating through the internet [70].

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) has approved a framework agreement for equipment processing and manufacturing with Hubei Yongbang Engineering Technology Co., Ltd., involving a total transaction amount not exceeding 20 million RMB [1] Group 1: Agreement Details - The agreement is for the year 2026 and includes processing and manufacturing services that meet the technical quality standards required by the company and its subsidiaries [1] - Services covered under the agreement include equipment manufacturing and installation, as well as electromechanical equipment and pipeline installation [1] - The agreement will be effective for one year from the date of approval by the board of directors [1]